title: Functional interaction between alpha2-adrenoceptors, mu- and kappa-opioid receptors in the guinea pig myenteric plexus: effect of chronic desipramine treatment.
abstract: The existence of a functional interplay between alpha(2)-adrenoceptor and opioid receptor inhibitory pathways modulating neurotransmitter release has been demonstrated in the enteric nervous system by development of sensitivity changes to alpha(2)-adrenoceptor, mu- and kappa-opioid receptor agents on enteric cholinergic neurons after chronic sympathetic denervation. In the present study, to further examine this hypothesis we evaluated whether manipulation of alpha(2)-adrenoceptor pathways by chronic treatment with the antidepressant drug, desipramine (10 mg/kg i.p. daily, for 21 days), could entail changes in enteric mu- and kappa-opioid receptor pathways in the myenteric plexus of the guinea pig distal colon. In this region, subsensitivity to the inhibitory effect of both UK14,304 and U69,593, respectively alpha(2A)-adrenoceptor and kappa-opioid receptor agonist, on the peristaltic reflex developed after chronic desipramine treatment. On opposite, in these experimental conditions, supersensitivity developed to the inhibitory effect of [D-Ala, N-Me-Phe4-Gly-ol5]-enkephalin (DAMGO), mu-opioid receptor agonist, on propulsion velocity. Immunoreactive expression levels of alpha(2A)-adrenoceptors, mu- and kappa-opioid receptors significantly decreased in the myenteric plexus of the guinea pig colon after chronic desipramine treatment. In these experimental conditions, mRNA levels of alpha(2A)-adrenoceptors, mu- and kappa-opioid receptors significantly increased, excluding a direct involvement of transcription mechanisms in the regulation of receptor expression. Levels of G protein-coupled receptor kinase 2/3 and of inhibitory G(i/o) proteins were significantly reduced in the myenteric plexus after chronic treatment with desipramine. Such changes might represent possible molecular mechanisms involved in the development of subsensitivity to UK14,304 and U69,593 on the efficiency of peristalsis. Alternative molecular mechanisms, including a higher efficiency in the coupling between receptor activation and downstream intracellular effector systems, possibly independent from inhibitory G(i/o) proteins, may be accounted for the development of supersensitivity to DAMGO. Increased sensitivity to the mu-opioid agonist might compensate for the development of alpha(2A)-adrenoceptor and kappa-opioid receptor subsensitivity. On the whole, the present data further strengthen the concept that, manipulation of alpha(2)-adrenergic inhibitory receptor pathways in the enteric nervous system entails changes in opioid inhibitory receptor pathways, which might be involved in maintaining homeostasis as suggested for mu-opioid, but not for kappa-opioid receptors.
authors.affiliation: Clinical and Applied Pharmacology Centre, University of Insubria and University of Pavia, via O Rossi 9, I-21100 Varese, Italy.
authors.forename: Luca
authors.initials: L
authors.lastname: Canciani
authors.forename: Cristina
authors.initials: C
authors.lastname: Giaroni
authors.forename: Elena
authors.initials: E
authors.lastname: Zanetti
authors.forename: Daniela
authors.initials: D
authors.lastname: Giuliani
authors.forename: Rossana
authors.initials: R
authors.lastname: Pisani
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Moro
authors.forename: Marco
authors.initials: M
authors.lastname: Trinchera
authors.forename: Francesca
authors.initials: F
authors.lastname: Crema
authors.forename: Sergio
authors.initials: S
authors.lastname: Lecchini
authors.forename: Gianmario
authors.initials: G
authors.lastname: Frigo
mesh_terms: D058647:Adrenergic alpha-2 Receptor Agonists; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000700:Analgesics / Q000494:pharmacology; D000701:Analgesics, Opioid / Q000494:pharmacology; D000818:Animals; D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology*; D044482:Benzeneacetamides / Q000494:pharmacology; D015153:Blotting, Western; D000068438:Brimonidine Tartrate; D003891:Desipramine / Q000494:pharmacology*; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)- / Q000494:pharmacology; D051676:G Protein-Coupled Inwardly-Rectifying Potassium Channels / Q000096:biosynthesis; D019204:GTP-Binding Proteins / Q000096:biosynthesis; D006168:Guinea Pigs; D066298:In Vitro Techniques; D008297:Male; D009197:Myenteric Plexus / Q000187:drug effects*; D010528:Peristalsis / Q000187:drug effects; D011759:Pyrrolidines / Q000494:pharmacology; D011810:Quinoxalines / Q000494:pharmacology; D012333:RNA, Messenger / Q000096:biosynthesis; D018341:Receptors, Adrenergic, alpha-2 / Q000187:drug effects*; D017473:Receptors, Opioid, kappa / Q000819:agonists / Q000187:drug effects*; D017450:Receptors, Opioid, mu / Q000819:agonists / Q000187:drug effects*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013574:Synaptosomes / Q000187:drug effects / Q000378:metabolism
chemical_list: D058647:Adrenergic alpha-2 Receptor Agonists; D000316:Adrenergic alpha-Agonists; D000700:Analgesics; D000701:Analgesics, Opioid; D000929:Antidepressive Agents, Tricyclic; D044482:Benzeneacetamides; D051676:G Protein-Coupled Inwardly-Rectifying Potassium Channels; D011759:Pyrrolidines; D011810:Quinoxalines; D012333:RNA, Messenger; D018341:Receptors, Adrenergic, alpha-2; D017473:Receptors, Opioid, kappa; D017450:Receptors, Opioid, mu; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D000068438:Brimonidine Tartrate; D019204:GTP-Binding Proteins; C045444:U 69593; D003891:Desipramine